An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension
Overview
The purpose of this study is to determine the safety and tolerability of topical C-KAD Ophthalmic Solution in reducing intraocular pressure in patients with ocular hypertension.
Full Title of Study: “A Pilot, Open-Label, Controlled Clinical Trial of C-KAD Ophthalmic Solution in Reducing Intraocular Pressure in Patients With Ocular Hypertension”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: April 2009
Interventions
- Drug: C-KAD Ophthalmic Solution
- 4 drops applied daily for 150 days
Arms, Groups and Cohorts
- Experimental: C-KAD Ophthalmic Solution
Clinical Trial Outcome Measures
Primary Measures
- Mean change in intraocular pressure from baseline
- Time Frame: 150 Days
Participating in This Clinical Trial
Inclusion Criteria
- Both eyes having intraocular pressure in the range of 22-30 mmHg at baseline – Both eyes having best corrected visual acuity better than 20/50 Exclusion Criteria:
- Advanced glaucoma – Closed or barely open anterior chamber or history of angle closure
Gender Eligibility: All
Minimum Age: 50 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Chakshu Research, Inc.
- Provider of Information About this Clinical Study
- Ellen Hoogeveen /Associate Director, Clinical & Regulatory Affairs, Chakshu Research, Inc.
- Overall Official(s)
- Ira Wong, MD, Study Director, Chakshu Research, Inc.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.